HC Wainwright Reiterates “Buy” Rating for Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $37.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 317.61% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Jefferies Financial Group began coverage on Pharming Group in a research report on Monday, December 9th. They set a “buy” rating and a $14.00 price objective for the company. Oppenheimer increased their target price on Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a research note on Friday, March 14th.

Pharming Group Trading Up 0.7 %

NASDAQ PHAR traded up $0.06 on Thursday, hitting $8.86. The company’s stock had a trading volume of 1,131 shares, compared to its average volume of 6,178. Pharming Group has a 52-week low of $6.65 and a 52-week high of $11.30. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The company’s 50-day simple moving average is $8.93 and its 200 day simple moving average is $8.60. The firm has a market cap of $602.75 million, a P/E ratio of -34.08 and a beta of -0.10.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The firm had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. Research analysts predict that Pharming Group will post -0.2 EPS for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.